ATE458732T1 - Verwendung von 4-imidazol-derivaten für zns- erkrankungen - Google Patents

Verwendung von 4-imidazol-derivaten für zns- erkrankungen

Info

Publication number
ATE458732T1
ATE458732T1 AT07703939T AT07703939T ATE458732T1 AT E458732 T1 ATE458732 T1 AT E458732T1 AT 07703939 T AT07703939 T AT 07703939T AT 07703939 T AT07703939 T AT 07703939T AT E458732 T1 ATE458732 T1 AT E458732T1
Authority
AT
Austria
Prior art keywords
imidazole derivatives
cns diseases
cns
diseases
imidazole
Prior art date
Application number
AT07703939T
Other languages
English (en)
Inventor
Guido Galley
Zbinden Katrin Groebke
Marius Hoener
Roger Norcross
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE458732T1 publication Critical patent/ATE458732T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07703939T 2006-01-27 2007-01-17 Verwendung von 4-imidazol-derivaten für zns- erkrankungen ATE458732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100938 2006-01-27
PCT/EP2007/050441 WO2007085556A2 (en) 2006-01-27 2007-01-17 Use of 4-imidazole derivatives for cns disorders

Publications (1)

Publication Number Publication Date
ATE458732T1 true ATE458732T1 (de) 2010-03-15

Family

ID=38051581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07703939T ATE458732T1 (de) 2006-01-27 2007-01-17 Verwendung von 4-imidazol-derivaten für zns- erkrankungen

Country Status (18)

Country Link
US (1) US8158668B2 (de)
EP (1) EP1981880B1 (de)
JP (1) JP2009524616A (de)
KR (1) KR101079914B1 (de)
CN (1) CN101374832B (de)
AR (1) AR059206A1 (de)
AT (1) ATE458732T1 (de)
AU (1) AU2007209380B2 (de)
BR (1) BRPI0706759A2 (de)
CA (1) CA2637308C (de)
DE (1) DE602007004949D1 (de)
ES (1) ES2338716T3 (de)
IL (1) IL192885A0 (de)
NO (1) NO20083356L (de)
RU (1) RU2008130448A (de)
TW (1) TW200738645A (de)
WO (1) WO2007085556A2 (de)
ZA (1) ZA200806457B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981497A2 (de) 2006-01-27 2008-10-22 F.Hoffmann-La Roche Ag Verwendung von substituiertem 2-imidazol aus imidazolin-derivaten
EP2076497B1 (de) 2006-10-19 2012-02-22 F. Hoffmann-La Roche AG Aminomethyl-4-imidazole
MX2009008255A (es) 2007-02-02 2009-08-12 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos taar1.
MX2009008776A (es) * 2007-02-13 2009-08-25 Schering Corp Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
CA2678036A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
EP2142538B1 (de) 2007-02-13 2011-10-26 Schering Corporation Derivate und analoge von chroman als funktionell selektive alpha2c-adrenorezeptor-agonisten
WO2009003867A1 (en) * 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
AU2009205539B2 (en) * 2008-01-18 2013-12-05 Allergan.Inc Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
CN102083805A (zh) * 2008-07-24 2011-06-01 弗·哈夫曼-拉罗切有限公司 4,5-二氢-唑-2-基衍生物
US20120190719A1 (en) * 2009-08-26 2012-07-26 Allergan, Inc. Methods of treating motor disorders with alpha-2b andrenergic receptor agonists
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AU2014229313B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
JP6310070B2 (ja) * 2013-10-07 2018-04-11 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物
CN103664788B (zh) * 2013-12-04 2015-11-25 湖北生物医药产业技术研究院有限公司 制备美托咪啶的方法
US10189844B2 (en) 2016-02-04 2019-01-29 Chiesi Farmaceutici S.P.A. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
EP3757102A1 (de) 2016-03-17 2020-12-30 F. Hoffmann-La Roche AG 5-ethyl-4-methyl-pyrazole-3-carboxamid-derivat mit wirkung als taar agonist
CN105884691B (zh) * 2016-06-02 2017-08-25 江苏恒瑞医药股份有限公司 一种制备右美托咪定及其中间体的方法
JP7343170B2 (ja) * 2017-05-12 2023-09-12 ボード オブ トラスティーズ オブ ザ サザン イリノイ ユニバーシティ オン ビハーフ オブ サザン イリノイ ユニバーシティ エドワーズビル 3,4,5-三置換-1,2,4-トリアゾールおよび3,4,5-三置換-3-チオ-1,2,4-トリアゾール、ならびにそれらの使用
CN107879979B (zh) * 2017-10-27 2020-08-25 广东莱佛士制药技术有限公司 一种右美托咪定的制备方法
MX2022005084A (es) 2019-10-31 2022-05-26 Escape Bio Inc Formas sólidas de un modulador del receptor s1p a.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7312245A (nl) * 1973-09-06 1975-03-10 Stamicarbon Werkwijze voor het bereiden van alphamethylstyreen bevattende blokcopolymeren.
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPH0733333B2 (ja) * 1986-12-12 1995-04-12 三井石油化学工業株式会社 脳機能改善薬
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB2256135B (en) 1991-05-31 1995-01-18 Orion Yhtymae Oy Transdermal administration of 4-substituted imidazoles
GB9521680D0 (en) 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
AU744798B2 (en) * 1997-12-04 2002-03-07 Allergan, Inc. Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1−置換−1−(1h−イミダゾール−4−イル)メタノール類
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
MXPA06000269A (es) * 2003-07-09 2006-04-07 Hoffmann La Roche Tiofenilaminoimidazolinas.
AU2004279336A1 (en) * 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MX2007003068A (es) * 2004-09-24 2007-05-21 Allergan Inc 4-(fenil-metil y fenil-metil substituido)-imidazol-2tionas como agonistas adrenergicos alfa2 especificos.

Also Published As

Publication number Publication date
AU2007209380A1 (en) 2007-08-02
NO20083356L (no) 2008-10-21
ES2338716T3 (es) 2010-05-11
JP2009524616A (ja) 2009-07-02
KR101079914B1 (ko) 2011-11-04
WO2007085556A3 (en) 2007-10-04
US8158668B2 (en) 2012-04-17
CN101374832B (zh) 2013-03-06
IL192885A0 (en) 2009-02-11
DE602007004949D1 (de) 2010-04-08
ZA200806457B (en) 2009-11-25
EP1981880A2 (de) 2008-10-22
CA2637308C (en) 2014-02-25
CA2637308A1 (en) 2007-08-02
WO2007085556A2 (en) 2007-08-02
KR20080088658A (ko) 2008-10-02
EP1981880B1 (de) 2010-02-24
BRPI0706759A2 (pt) 2011-04-05
TW200738645A (en) 2007-10-16
CN101374832A (zh) 2009-02-25
AR059206A1 (es) 2008-03-19
AU2007209380B2 (en) 2011-12-08
RU2008130448A (ru) 2010-03-10
US20070197622A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE458732T1 (de) Verwendung von 4-imidazol-derivaten für zns- erkrankungen
DE602005021132D1 (de) Ausgabeeinheit für Wertscheine
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DE602006015297D1 (de) 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BRPI0719389A2 (pt) Derivados de hidantoína utilizados como inibidores de mmp
CR10562A (es) Nuevos derivados de piridazina
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
CU23828B1 (es) Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
DE602006011363D1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
DK1916890T3 (da) Forbedrede egenskaber for græsendofytter
FI20065757A (fi) Beta-laktamaasin käyttö
DE112007000789A5 (de) Verwendung von Bora-tetraazepentalenen
FI20075600A0 (fi) Komponentin eliniän määritys
ATE552753T1 (de) Ausziehführung für schubladen
ATE469150T1 (de) Kristallformen eines imidazolderivats
NO20091266L (no) Fremgangsmåter for administrering av langvarige hypoglykemiske midler
NO20083328L (no) Fremgangsmåte for fremstilling av papir
FI20075505A (fi) Menetelmä silmälasien valmistamiseksi
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
ATE443991T1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1981880

Country of ref document: EP